Navigation Links
Innocoll Provides an Update on its Range of Advanced Wound Care and Related Collagen-based Products
Date:9/19/2011

ASHBURN, Va., Sept. 19, 2011 /PRNewswire/ -- Innocoll, Inc. announced the following update for its range of advanced wound care and related collagen-based products. Based on a series of recent regulatory approvals and product listings, Innocoll has added six more products in a variety of sponge, film, bilayer, powder, gel and spray formats that are available for commercialization in the US, EU and other markets such as Canada and New Zealand. These products include:  

  • CollaCare®, a range of advanced bioactive wound dressings for the management of chronic and acute wounds available in sponge, film and powder formats.
  • CollaCare® Dental, a lyophilized collagen matrix for the management of oral wounds including periodontal and other dental surgical wounds.  
  • Collexa®, an advanced bilayer wound dressing for the management of heavily exudating chronic wounds and burns.
  • Lidocoll®, an OTC topical analgesic available in collagen-based spray and gel formats containing 4% lidocaine hydrochloride for the relief of pain associated with minor burns, cuts, and skin irritations.
  • CollaGentle™, a collagen-based spray for skin conditioning and moisturizing.
  • Zorpreva™, a series of collagen-based absorbable hemostats for use in surgery including maxillofacial and dental surgeries.

Commenting on the update, Dr. Michael Myers, Innocoll's President and CEO said, "We have successfully expanded our portfolio of collagen-based products to include a wide range of presentations and applications. We are actively preparing for the commercialization of these products in the near future."

About Innocoll, Inc.

Innocoll is a privately held, biopharmaceutical company focused on biodegradable surgical implants and topically applied healthcare products. The company develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, CollaRx®, CollaFilm®, DermaSil™ and Liquicoll®. Approved products based on the Company's technologies include: Collatamp® G, Septocoll®, Collieva®, CollaCare®, Collexa®, Zorpreva™, and LidoColl®.

Other products in clinical and regulatory development include: CollaRx® Gentamicin Surgical Implant in phase 3 for prevention of surgical wound infections, Cogenzia® in phase 3 for the adjuvant treatment of infected diabetic foot ulcers, Xaracoll in phase 2b for the management of post-operative pain, and CollaGUARD®, for the prevention of surgical adhesions, which has been submitted for approval in the EU. For more information, please visit www.innocollinc.com.


'/>"/>
SOURCE Innocoll, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Innocoll Announces Top-line Results from its Phase 2 Clinical Trial Investigating XaraColl® for the Management of Post-operative Pain and Receives "Notice of Allowability" for XaraColl U.S. Patent Application
2. Innocoll Submits SPA for Cogenzia(TM) Phase III Clinical Trials for the Adjuvant Treatment of Diabetic Foot Infections
3. Innocoll Announces Dosing of Last Patient in Second US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Colorectal Surgery Patients
4. Innocoll Announces Dosing of Last Patient in US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Cardiac Surgery Patients
5. Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain
6. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections
7. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
8. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
9. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
10. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
11. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... , Sept. 27, 2017  Commended for their devotion ... notable awards. Ranked as number one in the South Florida ... time in Inc. 5000 yearly list, the national specialty pharmacy ... Armando Bardisa will soon be honored by SFBJ ... Set to receive his award in ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., ... analytics, today announced that it has been ranked #1 by ... Black Book™ Rankings 2017 User Survey. ZirMed was recognized ... for large hospitals and medical centers over 200 beds and ... Book,s healthcare technology user survey history. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Talented ... the lowdown on sciatica in a new episode of "Success Files," which is ... events and innovation and investigates each subject in-depth with passion and integrity. , ...
(Date:10/12/2017)... ... 12, 2017 , ... First Healthcare Compliance (FHC), an industry ... a range of technology and learning solutions at the 68th Annual American Healthcare ... be held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, ...
(Date:10/12/2017)... ... , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s ... design of the shoulder pad. The shoulder pad provides optimal support and full ... while using cold therapy. By utilizing ice and water that is circulated from an ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... Hair Restoration, has recently contributed a medical article to the newly revamped ... Dr. Mohebi’s article spotlights the hair transplant procedure known as Follicular Unit ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... of Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite ... program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the ...
Breaking Medicine News(10 mins):